<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638583</url>
  </required_header>
  <id_info>
    <org_study_id>HS-17-00746</org_study_id>
    <secondary_id>R01AG053798</secondary_id>
    <nct_id>NCT03638583</nct_id>
  </id_info>
  <brief_title>Alzheimer Prevention Trials (APT) Webstudy</brief_title>
  <official_title>Alzheimer Prevention Trials (APT) Webstudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for
      Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be
      at higher risk for developing AD dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The APT Webstudy will use web-based cognitive testing and questionnaires to generate a risk
      score which will be used to identify individuals who may be at an increased risk for
      developing AD dementia.

      Individuals who join the APT Webstudy will register at https://www.aptwebstudy.org/, sign an
      electronic informed consent form (ICF), provide basic demographic information and participate
      in web-based cognitive testing. Participants will return the APT Webstudy quarterly (every 3
      months) to complete the cognitive testing again.

      Based on the risk score and changes identified in the cognitive testing results, participants
      will be invited to visit a partnering clinical trial site for an in-person visit with
      biomarker testing and clinical assessment.

      The combined results of the web-based assessments, with the biomarker and clinical
      assessments, will allow an adaptive statistical algorithm to improve the selection of those
      at highest risk for developing AD.

      To Join the APT Webstudy, please visit https://www.aptwebstudy.org/.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Enrollment into Alzheimer's prevention research studies</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Referral into prevention research studies</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of individuals enrolled into Alzheimer's prevention studies</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200000</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Anyone who meets entry criteria is eligible to join the Webstudy. We anticipate 200,000
        individuals will join.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female at least 50 years of age

          -  no evidence of dementia

          -  willing to participate in remote longitudinal cognitive testing and possible referral
             for biomarker assessment based on risk

        Exclusion Criteria:

          -  N/A. Anyone can register for the APT Webstudy, however, only individuals identified
             using the risk algorithm will be referred for in-person biomarker assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Aisen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC ATRI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reisa Sperling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Cummings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>APT Webstudy Team</last_name>
    <phone>858-877-3135</phone>
    <email>info@aptwebstudy.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Https://Www.Aptwebstudy.Org</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>APT Webstudy Team</last_name>
      <phone>858-877-3135</phone>
      <email>info@aptwebstudy.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.aptwebstudy.org/welcome?utm_source=ctgov&amp;utm_medium=website&amp;utm_campaign=trialfinder</url>
    <description>APT Webstudy website</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Aisen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Prevention</keyword>
  <keyword>Web-Based</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

